Gaucher Disease-Associated Glucocerebrosidases Show Mutation-Dependent Chemical Chaperoning Profiles
Open Access
- 1 November 2005
- journal article
- research article
- Published by Elsevier in Chemistry & Biology
- Vol. 12 (11) , 1235-1244
- https://doi.org/10.1016/j.chembiol.2005.09.007
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Sustained therapeutic effects of oral miglustat (Zavesca, N‐butyldeoxynojirimycin, OGT 918) in type I Gaucher diseaseJournal of Inherited Metabolic Disease, 2004
- Pharmacological chaperone action on G-protein-coupled receptorsCurrent Opinion in Pharmacology, 2004
- Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher diseaseJournal of Inherited Metabolic Disease, 2004
- Pharmacologic Rescue of Conformationally‐Defective Proteins: Implications for the Treatment of Human DiseaseTraffic, 2004
- Pharmacological Enhancement of β-Hexosaminidase Activity in Fibroblasts from Adult Tay-Sachs and Sandhoff PatientsJournal of Biological Chemistry, 2004
- The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statementJournal of Inherited Metabolic Disease, 2003
- Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryThe American Journal of Medicine, 2002
- Gaucher disease: perspectives on a prototype lysosomal diseaseCellular and Molecular Life Sciences, 2002
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Partial Enzyme Deficiencies: Residual Activities and the Development of Neurological DisordersDevelopmental Neuroscience, 1983